Biotechnology company Nutcracker Therapeutics has appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer.
The California-based company develops RNA therapies through its proprietary technology platform, NTX-0250.
Igor Khandros, Ph.D., cofounder and Chief Executive Officer of Nutcracker Therapeutics, said:
“Rob’s extensive background, which includes driving successful clinical development programs within the pharmaceutical and biotechnology industries, gives us full confidence in his ability to oversee the continuous evolution of our pipeline.
“The biological versatility of RNA equips Nutcracker Therapeutics with the tools to reimagine the treatment landscape of oncology, and beyond.
“Dr Schott’s robust track record adds a new dimension of invaluable industry know-how to a team of talented individuals working to bring transformative RNA therapies to patients.”
Dr Schott joins Nutcracker Therapeutics from Sangamo Therapeutics, where, as Senior Vice President and Head of Development, he spearheaded clinical strategy across numerous programmes.
Dr Schott previously served as Chief Medical Officer at Chorus – an operationally independent subsidiary of Eli Lilly and Company
There, he led the implementation of innovative processes designed to achieve clinical proof-of-concept more efficiently for early-stage drug candidates.
Dr Schott said:
“I see RNA as a drug modality with enormous potential, so I immediately connected with Nutcracker Therapeutics’ distinct methodology of RNA drug development.
“The unique ability of the company’s technology platform to rapidly design and interrogate RNA molecules will be key to realising the therapeutic potential of this drug class within oncology and beyond.
“I look to utilise my clinical expertise to advance Nutcracker Therapeutics’ pipeline and contribute to a culture built on dedication to improving patient lives.”
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
Listen: Longevity, Eastern wisdom and Western science
Fundamental principles of healthcare digital twins
Tackling the diagnostic testing sustainability problem
Gym-going men ‘unaware’ of protein risk to fertility
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI5 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds